Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming - Scorecard - MDSpire
Advertisement
Metabolic cell competition in the glioblastoma tumour microenvironment: glucose, glutamine, and lactate as determinants of immune exclusion and targets for pharmacological reprogramming
Clinical Scorecard: Metabolic Competition Among Cells in the Glioblastoma Microenvironment: The Role of Glucose, Glutamine, and Lactate in Immune Exclusion and Potential Pharmacological Interventions
At a Glance
Category
Detail
Condition
Glioblastoma (GBM)
Key Mechanisms
Metabolic competition among GBM cells, immunosuppressive myeloid cells, and T lymphocytes driven by glucose and glutamine consumption.
Target Population
Adults diagnosed with glioblastoma, median age 64 years.
Care Setting
Oncology and neurology clinical settings.
Key Highlights
GBM has a median overall survival of 14 to 16 months despite current treatments.
The tumor microenvironment is immunosuppressive, affecting T cell function.
Metabolic competition leads to a hierarchy that impairs anti-tumor immunity.
Pharmacological interventions can disrupt metabolic dependencies of GBM cells.
Mebendazole shows potential as a repurposed treatment with survival benefits.
Guideline-Based Recommendations
Diagnosis
Molecular stratification by MGMT promoter methylation and IDH mutation status.
Management
Maximal safe surgical resection followed by concurrent temozolomide and radiotherapy.
Monitoring & Follow-up
Assessing the impact of metabolic interventions on T cell function and tumor progression.
Risks
Immunotherapy trials have shown disappointing results due to the immunosuppressive microenvironment.
Patient & Prescribing Data
Patients with glioblastoma, particularly those with IDH-wildtype tumors.
Targeting metabolic pathways may enhance T cell function and disrupt tumor cell competition.
Clinical Best Practices
Consider pharmacological ketosis to enhance T cell effector function.
Explore glutamine antagonism and glucose restriction as therapeutic strategies.
Monitor metabolic competition dynamics within the tumor microenvironment.
